Opinion
Video
This program was possible with support from Bayer.
The Role of Combination Therapy in mCRPC
Author(s):
Rashid K. Sayyid, MD, MSc, discusses the role of combination therapy in metastatic castrate-resistant prostate cancer.
This is a synopsis of an Educated Patient Sound Bites series featuring Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute; Rashid K. Sayyid, MD, MSc, of the University of Toronto; and Reginald Tucker-Seeley, MA, ScM, ScD, of ZERO Prostate Cancer.
Dr Rashid K. Sayyid discusses PARP inhibitors like olaparib and rucaparib in combination with other therapies. For example, enzalutamide-olaparib was approved based on TRITON3 for certain mutations, while olaparib-abiraterone was approved first-line for BRCA-mutated cancer per PROPEL. He explains PARP inhibitors may radiosensitize, improving radium Ra 223 dichloride efficacy.
The ongoing COMRADE phase 1/2 trial established olaparib-radium dosing in phase 1 and showed 6-month 57% radiographic progression-free survival and 56% 1-year overall survival. Phase 2 is now examining olaparib-radium efficacy for radiographic progression-free survival with 213 patients. Upcoming results over next few years.
In summary, Dr. Sayyid overviews emerging prostate cancer approaches, including PARP inhibitor combinations with antiandrogens like enzalutamide or abiraterone for certain mutations, as well as combinations with radium Ra 223 dichloride now under phase 2 investigation.
*Video synopsis is AI-generated and reviewed by CURE editorial staff.
